DOCSLIB.ORG

Chinese Life Sciences Inward Visit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Chinese Life Sciences Visit – 4 July 1 Victoria St Conference Centre, London The China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) is bringing a delegation to the UK in July, as part of their co-operation with UKTI under the Joint Economic Trade Commission Healthcare Working Group. This event will give you the opportunity to find out more about how CCCMHPIE, UKTI and the China-Britain Business Council (CBBC) can help UK companies doing business in China, and network with the delegation of Chinese Life Sciences companies. Places are limited at this event, to confirm a place, email – [email protected] providing a short paragraph about your company by 27 June. Time Agenda 10.30 – 11:00 Registration Introductory presentations from Dr Mark 11.00 - 11.20 Treherne, UKTI and Madam MENG Dongping, CCCMHPIE 11:20 -11:40 Presentations from the Chinese delegation 11:40 -11:50 Case study 11:50 -12:00 Closing remarks 12:00 -14:00 Networking and Lunch Chinese Delegation Name Organisation Title ZHOU Xiaoming Chinese Embassy in the UK Minister Commercial Counsellor MENG CCCMHPIE, Vice President – Dongping under MOFCOM Lead of the Delegation State Administration of Traditional Chinese Medicine of the People's Republic of China Vice Director-General WU Zhendou (SATCM) Ministry of Commerce of the People's Republic of China Deputy Director YU Miao (MOFCOM) CCCMHPIE, Department of GUO Xiaodan under MOFCOM Pharmaceuticals ZHANG Li CCCMHPIE, Department of Law Affairs (Ally) under MFOCOM of Strategic Planning Institute of Chinese Materia Medica of China Academy of LIJianrong Chinese Medical Sciences Researcher Institute of Chinese Materia Medica of China Academy of LIANG Aihua Chinese Medical Sciences Researcher China Beijing Tongrentang LI Xia (Group) Co.,Ltd. Chief Engineer China Beijing Tongrentang FENG Li (Group) Co.,Ltd. Assistant to the President JIANG Xiaoyue Zhejiang Medicines Co.,Ltd. Director in Chief Director of the Department HE Yimin Zhejiang Medicines Co.,Ltd. of International Trade DAI Biao Tasly Group CEO Beijing Holley-Cotec Chief Director of MU Zexun Pharmaceuticals Co., Ltd. International Marketing Orient International Holding Shanghai Rongheng International Trading Co., WANG Huijuan Ltd General Manager Yangtze River Head of the International XIE Li Pharmaceutical Group Department North China Pharmaceutical WANG Lihong Group Corporation Chief Director of Marketing Youcare Pharmaceutical HE Yingjun Group Co.Ltd Vice General Manager Company Information China Chamber of Commerce for Imp.& Exp. of Medicines and Health Products Founded in May 1989, China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), is the leading and most influential national trade association in China with a mission to promote the international trade and cooperation in medicinal and health products. CCCMHPIE is directly under the Ministry of Commerce of China, has a diverse membership of more than 2,400 companies including most of the major manufacturers and trading companies of pharmaceutical and health products across China. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences The Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences is one of the oldest national institutions specially engaged in the research of Chinese materia medica in China. At present, there are more than 136 on-going research projects. Since the foundation of the institute, 18 projects have been awarded national prizes, 57 projects awarded ministerial and bureau prizes and 172 projects awarded academic prizes. To date, the institute has developed 32 new medicines. In 2011, Professor TU You, was honored the Lasker~DeBakey Clinical Medical Research Award of U.S.A. for her outstanding contribution offered during the development of artemisinin. Tasly Group Co.,Ltd. Incorporated in 1994 with a registered capital of CNY240 million, Tasly Group currently controls over 50 subsidiaries and branches with a staff of 13,000. The group a network of more than 30 countries and regions and has 22 branches and 3 representative offices worldwide. In 2012 Tasly achieved sales of CNY21.3 billion, in which $68.8 million was obtained overseas. Yangtze River Pharmaceutical (Group) Co., Ltd. Yangtze River Pharmaceutical Group (hereinafter refers to as YRPG) was founded in 1971, with over 9000 employees and a total floor area of over 2 million square meters. YRPG is a cross-region pharmaceutical group, integrated with science and technology, industry and trading, combining production, learning and research. YRPG has been ranked in the top 5 of national pharmaceutical industry for over 10 years. YRPG was ranked top 1 in China Pharmaceutical Industry Top 100 which was issued by the Ministry of Industry and Information Technology (MIIT) in 2009 and 2010. Zhejiang Medicine Co., Ltd. Zhejiang Medicine Co., Ltd. (hereinafter refers to as ZMC) is a manufacturer and supplier of pharmaceutical, human and animal nutrition products. ZMC Xinchang Pharma employs 3,300 people operating a 500,000m2 manufacturing facility, and maintains assets of USD 568 million. 2009 revenue was USD 448 million. ZMC Xinchang Pharma manufactures and supplies a broad product line specializing in fat soluble vitamins, carotenoids, active pharmaceutical ingredients (APIs) through both synthetic process and fermentation. China Beijing Tong Ren Tang Group Co.,Ltd In 1992, Beijing Tong Ren Tang Group Co., Ltd was established which became a solely state-owned company duly authorized by Beijing Municipal Government to run national assets in 2001. The company registered capital was 235.44 million yuan. It has owned more than 1500 products, 83 production lines passing domestic and foreign GMP certification and over 1500 retail terminals. Beijing TRT has 84 pharmacies in 16 foreign countries and regions. Orient Int’L Holding, Shanghai Rongheng Int’L Trading Co., Ltd. Founded in 1992, OIH Shanghai Rongheng specializes in healthcare products, mainly in marketing Generics in South-east Asia and African countries, where the official product registrations are required with the drugs authorities. They are involved in the entire process of GMP pre-auditing on Chinese Generics producers, products registrations, marketing plans and promotion. They have a range of products including tablets, capsules, liquid injections, powder for injections, skin screams and ointments, eye ointments, biological products, sutures, surgical blades. They also market surgical disposables in Eastern Europe. NCPC International Corp. NCPC Group was founded in 1953 and includes 31 affiliates, including API and formulations. For API, many products have CEP and EGMP. For formulation, towards regulated market, we had established two new facility, one is NCPC New Formulation Branch Factory, another is NCPC Hebei Huamin Pharmaceutical Co., Ltd. NCPC New Formulation Branch Factory is the production base for formulation of non-penicillin and non-cephalosporin, covers an area of 388 acres, total investment is RMB 2.6 billion. NCPC Hebei Huamin Pharmaceutical Co., Ltd. is the production base for cephalosporins in NCPC and the largest production base for cephalosporins in China. Covering an area of 388 acres, and the total investment is RMB 1.2 billion. Beijing Holley-Cotec Pharmaceuticals Co., Ltd Established in 1992, Beijing Holley-Cotec Pharmaceuticals Co., Ltd is one of the leading pharmaceutical companies in the R&D, manufacturing and marketing of anti- malaria in the world. With their brand “Duo-Cotecxin” in Africa and Southeast Asia, they have a good network of distribution and marketing throughout major endemic countries, especially the sub-Sahara areas. With the WHO GMP certified formulation facility in Jiaxing, Zhejiang province, their business plan is to prequalify our Duo- Cotecxin in WHO Geneva in the near future. They are very interested in exploring the possibility of licensing in good products for African market, Chinese market and even for EU market by partnering with medium sized pharmaceuticals company in the EU. Shanghai Medicines & Health Products Import & Export Co. Ltd. Shanghai Medicines and Health Products Import and Export Co., Ltd. was incorporated in 1986. Their business focus on import and export operations for Medicines and Health Products. Their major business lines include Active Pharmaceutical Ingredients, Medicines, Health Products, Herbal Extracts, Chinese Medicated Herbs, Surgical Dressing, Professional Medical Device, Hospital Appliance, Domestic Healthcare Instrument. Annual turnover is 180-200million USD. .
Recommended publications
  • Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1

    Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1

    KURE 3/31/2018 China Healthcare: Potential Opportunities From One Of The Fastest Growing Major Global Healthcare Markets1 An Overview of the KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) 1. Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2015. Retrieved 3/31/2018 [email protected] 1 Introduction to KraneShares About KraneShares Krane Funds Advisors, LLC is the investment manager for KraneShares ETFs. Our suite of China focused ETFs provides investors with solutions to capture China’s importance as an essential element of a well-designed investment portfolio. We strive to provide innovative, first to market strategies that have been developed based on our strong partnerships and our deep knowledge of investing. We help investors stay up to date on global market trends and aim to provide meaningful diversification. Krane Funds Advisors, LLC is majority owned by China International Capital Corporation (CICC). 2 Investment Strategy: KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The KURE securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.
  • 2018 Unaudited Semiannual Report

    2018 Unaudited Semiannual Report

    BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) Contents Pages Management and Administration 1 Report of the Manager to the Unitholders 2 Statement of Financial Position (Unaudited) 3 Investment Portfolio (Unaudited) 4 – 5 Statement of Movements in Investment Portfolio (Unaudited) 6 – 9 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) MANAGEMENT AND ADMINISTRATION Manager Directors of the Manager BOCOM International Asset Management Limited TAN Yueheng 9/F, Man Yee Building LI Ying 68 Des Voeux Road Central CHENG Chuange Central Hong Kong Trustee and Registrar Bank of Communications Trustee Limited 1/F, Far East Consortium Building 121 Des Voeux Road Central Central Hong Kong PRC Custodian HSBC Bank (China) Company Limited 33/F, HSBC Building, Shanghai ifc 8 Century Avenue, Pudong Shanghai Legal Counsel to the Manager Deacons 5/F, Alexandra House 18 Chater Road Central Hong Kong Auditor PricewaterhouseCoopers 21/F, Edinburgh Tower 15 Queen’s Road Central Hong Kong - 1 - SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) REPORT OF THE MANAGER TO THE UNITHOLDERS The A-share market under-performance in 1H2018 can be attributed to two main factors: 1) the United States entered an interest rate hike cycle, which caused wide concern about the emerging market’s debt problems.
  • Interview with Beijing Tong Ren Tang/Science Arts

    Interview with Beijing Tong Ren Tang/Science Arts

    [ Interview ] Mr Tan Lee Huak, owner of Science Arts Co Pte Ltd. Interview with Beijing Tong Ren Tang/Science Arts eijing Tongrentang, was founded in Kangxi 8. It is a famous time-honored brand in the Traditional Chinese Medicine industry. Science Arts collaborated Bwith Beijing Tong Ren Tang in 2004 and brought this well established brand to Singapore. Beijing Tong Ren Tang has a long Beijing Tong Ren Tang has outlets in many countries in the Asia history, being founded in the Kangxi Pacific. Its headquaters is in Beijing, China. The company has period, in 1669. Can you share with collaborated with more than 20 distributors worldwide. They us how the collaboration between have stores in the UK, Australia, Canada and countries in the Asia Pacific. Beijing Tong Ren Tang and Science It has also partnered with various distributors and companies in different Arts came about? countries. In Malaysia, they have partnered with “Hai Ou” to distibute their products. Here in Singapore, Science Arts is its sole distributor. Science Arts and Beijing Tong Ren Tang went into a collaboration in 2004. 1146 ■ Volume 11 > Number 16 > 2007 www.asiabiotech.com [ Interview ] What is Science Arts history and Science Arts have been around for 30 odd years. It was set up how did it come about? by a group of young passionate fresh graduates from The Chinese High School in the 1960s. The collaboration with Beijing Tong Ren Tang is 51% stakes held by Science Arts and 49% belongs to Beijing Tong Ren Tang. What are some of the measures that The side effects of most of our products are minimal.
  • Healthcare Sector

    Healthcare Sector

    19 August 2013 Sector Weekly Healthcare Sector Healthcare Sector Weekly Dose Valuation summary Company Ticker CCY Px Mkt ––––– P/E ––––– EPS CAGR –––– PEG –––– –––– P/B –––– –––– ROE –––– This weekly product is designed to provide investors with key sector cap '13E '14E '15E ('12E -'15E) '13E '14E '15E '13E '14E '15E '13E '14E '15E updates and our attempt to identify (USD) (x) (x) (x) (%) (x) (x) (x) (x) (x) (x) (%) (%) (%) stock implications and insights. Shandong Weigao Group Medical 1066 -HK HKD 8.09 1,965 24.2 19.9 16.4 22 1.1 0.9 0.7 2.9 2.6 2.3 12.1 13.2 14.3 Polymer Co. Ltd. Class H Topics this week: Bribery investigation, China Shineway Pharmaceutical 2877 -HK HKD 12.72 1,356 11.8 10.5 9.4 12 1.0 0.9 0.8 1.8 1.7 1.5 16.0 16.3 16.5 H7N9 resurfacing, NDRC might adjust Group Limited originator drug px, June ’13 hospital United Laboratories International 3933 -HK HKD 2.92 613 18.3 13.0 10.6 26 0.7 0.5 0.4 0.7 0.7 0.7 3.8 5.2 6.1 patient traffic data Holdings Ltd. Sinovac Biotech Ltd. SVA -US USD 4.61 254 -26.3 -43.9 46.1 2.3 2.6 2.7 -8.7 -6.0 5.9 Companies mentioned: Weigao (1066-HK), Shineway (2877.HK) and The China Nepstar Chain Drugstore NPD -US USD 1.58 156 21.3 Ltd. Sponsored ADR United Labs (3933.HK), Sinovac (SVA.O) and Nepstar (NPD.N) Source: Factset/Bloomberg SAIC anti-bribery investigation to begin: The State Administration for Industry and Commerce (SAIC) has initiated a round of bribery investigation that is expected to last 3 months until November ‘13.
  • China Pharmaceutical Newsletter

    China Pharmaceutical Newsletter

    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
  • Pharmaceuticals in China

    Pharmaceuticals in China

    INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS CLICK TO VIEW Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom Research, Related Studies, Corporate Use License 8 Pharmaceuticals in China China Industry Study with Forecasts to 2010 & 2015 Study #2024 | February 2006 | $4800 | 240 pages The Freedonia Group 767 Beta Drive www.freedoniagroup.com Cleveland, OH • 44143-2326 • USA Toll Free US Tel: 800.927.5900 or +1 440.684.9600 Fax: +1 440.646.0484 E-mail: [email protected] Study #2024 February 2006 Pharmaceuticals in China $4800 240 Pages China Industry Study with Forecasts to 2010 & 2015 Table of Contents INTRODUCTION Shipments .......................................62 Corticosteroids ............................ 115 Types of Medicines ............................63 Estrogens & Combinations ............. 115 Astragalus ....................................64 Other Hormones ........................... 116 EXECUTIVE SUMMARY Atractylodes ..................................66 Shipments ..................................... 117 Bupleurum ....................................67 Biologicals & Vaccines ........................ 119 MARKET ENVIRONMENT China Root ....................................67 Demand ......................................... 120 General ..............................................4 Cinnamon .....................................68 Vaccines ..................................... 120
  • Completing the Deal

    Completing the Deal

    termsheet April 2018 Issue 24 Completing the Deal industry insight An Interview with Dr Fintan Walton, Are Traditional Chinese Medicines Founder and Chief Executive of PharmaVentures and Plant Extract Treatments the Basis of New Licensing and M&A As Fintan Walton, the Founder and CEO of PharmaVentures, puts it himself, Growth? he was “fortunate enough to be able to enter the world of pharmaceuticals Eric Liu when the explosion of biotechnology Business Analyst, PharmaVentures Limited took off in the 1970’s and 1980s”. He Traditional Chinese Medicines (TCMs) are gaining was educated at Trinity College, Dublin interest worldwide. However despite being as a geneticist and entered the world practised by significant numbers of people in more of biotechnology in the UK by joining Celltech, the first biotech than 140 countries, the absence of robust evidence of efficacy in Europe, in the early 1980s. What Fintan finds fascinating about and safety in conventional clinical trials remains a key challenge that period was that the technology being developed enabled in mainstream commercial adoption, through licensing and M&A scientists to really understand the basis of disease and hence, transactions. Against this backdrop 2017 was a milestone year. The come up with truly break-through medicines as more and more University of Oxford opened its first Chinese Medicine Research biotech companies emerged worldwide. “Their research led to Centre on 6th December, which is one of the first research centres inventions and so the opportunity to license patents and do deals in the West that solely focuses on the study of herbal extracts became a real driver in the biotech industry”.
  • About the China Academy of Chinese Medical Sciences About the Coca-Cola Company

    About the China Academy of Chinese Medical Sciences About the Coca-Cola Company

    [ Industry Watch ] About the China Academy of Chinese Medical Sciences The China Academy of Chinese Medical Sciences is China’s national center for research, healthcare and education in traditional Chinese medicine. It is administered under the Ministry of Public Health through the State Administration of Traditional Chinese Medicine of the People’s Republic of China. The academy employs 3100 professionals, including 800 doctors and professors working in 11 research institutions, five hospitals and clinics, and several educational and publishing branches. It is the most respected and trusted group engaged in research, education, and practice in traditional Chinese medicine. About The Coca-Cola Company The Coca-Cola Company is the world’s largest nonalcoholic beverage company. Along with the Coca-Cola® trademark, recognized as the world’s most valuable brand, the company markets four of the world’s top five nonalcoholic sparkling beverage brands (including Coca-Cola®, Diet Coke®, Fanta® and Sprite® beverages), and a wide range of other nonalcoholic beverages, (including diet and light beverages, waters, juices and juice drinks, teas, coffees, and energy and sports drinks). Through the world’s largest beverage distribution system, consumers in more than 200 countries enjoy the company’s beverages at a rate exceeding 1.4 billion servings each day. ■ Contact details: China Academy of Chinese Medical Sciences Address: No.16 Nanxiaojie, Dongzhimen nei, Beijing 100700 P.R.China. Tel: +86 10 64016387 Email: [email protected] URL: www.cacms.ac.cn Contact Details: The Coca-Cola Company Address: P. O. Box 1734 Atlanta, GA 30301 USA Tel: +1 (404) 515 4400 Fax: +1 (404) 515 0430 URL: www.thecoca-colacompany.com www.asiabiotech.com Volume 11 > Number 21 > 2007 ■ 1421 [ Industry Watch ] CHINA Greater China Corporation to Open TRT Wellness Centers reater China Corporation announced the formation of Tong Ren Tang Wellness Corporation in partnership with TRT USA Corp.
  • Company Report: Sinopharm

    Company Report: Sinopharm

    Company Report: Sinopharm Group Co. Ltd. (01099 HK) Kay Mai 麦梓琪 公司报告：国药控股 (01099 HK) +86 755 23976685 [email protected] 国泰君安研究 2 March 2017 PRC's Largest Pharmaceutical Distributor, “Accumulate” 中国最大的医药分销商，“收集” GTJA ResearchGTJA Sinopharm is the largest pharmaceutical distributor and retailer in the Rating: Accumulate PRC, with sustainable above-industry growth. It took about 16.0% of market share in the pharmaceutical distribution industry and approximately 2.7% of market share in retail pharmacy business in 2015, according to the Ministry of 评级： 收集 Commerce in the People's Republic of China ("MOFCOM"). Sinopharm will benefit from further industry consolidation and will 6-18m TP 目标价: HK$39.89 solidify its leading position in for the foreseeable future. We believe recent polices such as the two-invoice system, unannounced Inspections, and stricter 股价： HK$36.550 Share price GSP will drive out small- and medium-sized distributors, which is likely to boost the market share and maintain the above-average growth of the Company. Revenue is estimated to grow by 12.9%, 12.8% and 12.8% YoY to Stock performance 股价表现 RMB256,337 million, RMB289,268 million and RMB326,410 million in respectively, as a result of 1) stable growth of the 50.0 % of return period FY2016-FY2018, 45.0 pharmaceutical distribution segment deriving from the combinational effect of 40.0 market share gaining growth from direct sales as well as the loss in indirect 35.0 30.0 sales triggered by industry consolidation, 2) fast expansion of the retail 25.0 business and its integration impact, and 3) a promising outlook for innovative 20.0 15.0 businesses such as financial leasing.
  • Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1

    Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1

    KURE 12/31/2020 China Healthcare: Potential Opportunities From One Of The Fastest Growing Major Global Healthcare Markets1 An Overview of the KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) 1. Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2017, last updated on 4/7/2020. [email protected] 1 Introduction to KraneShares About KraneShares Krane Funds Advisors, LLC is the investment manager for KraneShares ETFs. Our suite of China focused ETFs provides investors with solutions to capture China’s importance as an essential element of a well-designed investment portfolio. We strive to provide innovative, first to market strategies that have been developed based on our strong partnerships and our deep knowledge of investing. We help investors current on global market trends and aim to provide meaningful diversification. Krane Funds Advisors, LLC is majority owned by China International Capital Corporation (CICC). 2 Investment Strategy: KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and the KURE United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.
  • Changing Healthcare

    Changing Healthcare

    Changing Healthcare ACTCM students learn how to apply ancient wisdom to Apply Online Master of Science in Traditional Chinese Medicine www.actcm.edu/apply Doctorate of Acupuncture and Chinese Medicine modern healthcare practices. Chinese Medicine is a medical Submit the following: • Official Transcript(s) from all system that has been used for thousands of years to prevent, colleges attended • Personal Statement diagnose, and treat disease. It is based on the belief that • 2 Letters of Recommendation qi (the body’s vital energy) flows along meridians (channels) • Completed Application Form • Professional Resume in the body and keeps a person’s physical, spiritual, emotional • Application Fee and mental health in balance. Chinese medical modalities • 2 Passport Size Photos include acupuncture, diet, herbal therapy, meditation, ACTCM Admissions Team 455 Arkansas Street massage and exercise. San Francisco, CA 94107 Phone: (415)401-0464 Email: [email protected] www.actcm.edu ACTCM Graduates Lead the Field As… Acupuncturists Without Borders who give Acupuncturists who set up private practices medical aid to communities in crisis. around the country. Herbalists who grow herbs and create Educators who publish on TCM, wellness, herbal pharmacies. nutrition, and holistic healthcare. Healers who establish integrative health centers. Practitioners who are leading the way towards integrative healthcare in hospitals and clinics. Experts at forefront of healthcare research, ACTCM is Transforming AOM Education teaching and policy making. Through our merger with California Institute of Integral Studies (CIIS) we are advancing opportunities for the holistic care of mind, body and spirit. ACTCM at CIIS is creating clinic services that explore the interface between Chinese medicine and mental health.
  • Beijing Tong Ren Tang Chinese Medicine Company Limited 北京同仁堂國藥有限公司

    Beijing Tong Ren Tang Chinese Medicine Company Limited 北京同仁堂國藥有限公司

    Beijing Tong Ren Tang ChineseMedicineCompanyLimited RenTang Beijing Tong BeijingBeijing TongTong RenRen TangTang ChineseChinese MedicineMedicine CompanyCompany LimLimitedited 北京同仁堂國藥有限公司北京同仁堂國藥有限公司 (incorporated(incorco porated inin HongHong KongKoongg withwith limitedlimitedd lliliability)ability) （於香港註冊成立之有限公司）（於香港註冊冊成立之立之有限公司） StockStock codecoodde 股份股份代號：份代號：818138388 北京同仁堂國藥有限公司 Beijing Tong Ren Tang Chinese Medicine Company Limited 北京同仁堂國藥有限公司 www.tongrentangcm.com Annual Report2013 Annual 年報 2013 Annual Report 年報 password####TRT8138 CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report,